Abstract
Parkinson’s disease is a neurological disorder characterized by chronic progressive degeneration of nigrostriatal dopaminergic system. Although stereotactic surgery such as deep brain stimulation has been performed as surgical therapy, intracerebral cell grafting attracts increasing attention as new surgical therapy. In this review, genetically modified cell line grafting for the treatment of Parkinson’s disease will be summarized.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aebischer P, Schluep M, Deglon N, et al (1996) Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 2:696–699
Emerich DF, Winn SR, Christenson L, et al (1992) A novel approach to neural trans-plantation in Parkinson’s disease: Use of polymer-encapsulated cell therapy. Neurosci Biobehav Rev 16:437–447
Yoshida H, Date I, Shingo T, et al (2003) Stereotactic transplantation of a dopamine-producing capsule into the striatum for treatment of Parkinson disease: A preclinical primate study. J Neurosurg 98:874–881
Date I, Shingo T, Yoshida H, et al (2000) Grafting of encapsulated dopamine-secreting cells in Parkinson’s disease: Long-term primate study. Cell Transplant 9:705–709
Subramanian T, Emerich DF, Bakay RA, et al (1997) Polymer-encapsulated PC-12 cells demonstrate high-affinity uptake of dopamine in vitro and 18F-Dopa uptake and metabolism after intracerebral implantation in nonhuman primates. Cell Transplant 6:469–477
Date I, Shingo T, Ohmoto T, et al (1997) Long-term enhanced chromaffin cell survival and behavioral recovery in hemiparkinsonian rats with co-grafted polymer-encapsulated human NGF-secreting cells. Exp Neurol 147:10–17
Date I, Shingo T, Yoshida H, et al (2001) Grafting of encapsulated genetically modified cells secreting GDNF into the striatum of parkinsonian model rats. Cell Transplant 10:397–401
Fujiwara K, Date I, Shingo T, et al (2003) Reduction of infarct volume and apoptosis by grafting of encapsulated basic fibroblast growth factor-secreting cells in a model of middle cerebral artery occlusion in rats. J Neurosurg 99:1053–1062
Yasuhara T, Shingo T, Kobayashi K, et al (2004) Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson’s disease. Eur J Neurosci 19:1494–1504
Shingo T, Date I, Yoshida H, et al (2002) Neuroprotective and restorative effects of intrastriatal grafting of encapsulated GDNF-producing cells in a rat model of Parkinson’s disease. J Neurosci Res 69:946–954
Uchida S, Suzuki Y, Araie M, et al (2003) Factors secreted by human amniotic epithelial cells promote the survival of rat retinal ganglion cells. Neurosci Lett 341: 1–4
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag Tokyo
About this paper
Cite this paper
Date, I., Shingo, T., Yasuhara, T. (2006). Genetically Modified Cell Line Grafting for the Treatment of Parkinson’s Disease. In: Kanno, T., Kato, Y. (eds) Minimally Invasive Neurosurgery and Multidisciplinary Neurotraumatology. Springer, Tokyo. https://doi.org/10.1007/4-431-28576-8_17
Download citation
DOI: https://doi.org/10.1007/4-431-28576-8_17
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-28551-9
Online ISBN: 978-4-431-28576-2
eBook Packages: MedicineMedicine (R0)